Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases... Show more
a developer of technology and therapeutics for rare diseases
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| DSHZX | 13.86 | 0.08 | +0.58% |
| Brinker Capital Destinations Shelter Z | |||
| VSVIX | 39.72 | N/A | N/A |
| Victory Integrity Small-Cap Value Y | |||
| OIGIX | 25.89 | N/A | N/A |
| Invesco International Growth R6 | |||
| HDQVX | 21.27 | N/A | N/A |
| Janus Henderson International Div S | |||
| CGIEX | 50.65 | -0.17 | -0.33% |
| American Funds Intl Gr and Inc 529-E | |||
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | +5.36% | ||
| ALEC - ARCT | 61% Loosely correlated | N/A | ||
| AXON - ARCT | 49% Loosely correlated | +0.10% | ||
| VCYT - ARCT | 42% Loosely correlated | -2.76% | ||
| CRSP - ARCT | 41% Loosely correlated | -1.03% | ||
| QSI - ARCT | 40% Loosely correlated | +0.12% | ||
More | ||||
The 10-day RSI Oscillator for ARCT moved out of overbought territory on September 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In 28 of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 72 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ARCT broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
ARCT moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARCT crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
The 50-day moving average for ARCT moved above the 200-day moving average on August 26, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +13.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 219 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 126 of 159 cases where ARCT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.436) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (22.026) is also within normal values, averaging (427.627).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.